UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of September 2025
Commission
File Number: 001-42796
Nasus
Pharma Ltd.
Yigal
Alon 65
Tel
Aviv, Israel 6744317
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
CONTENTS
On
September 3, 2025, the Board of Directors (the “Board”) of Nasus Pharma Ltd. (the “Company”) appointed Dan Teleman,
the Company’s Chief Executive Officer, to serve as a director on its Board. Mr. Teleman was appointed to the Board as permitted
under the Company’s Amended and Restated Articles of Association due to a vacancy on the Board. Mr. Teleman will serve as a Class
III director, which term will expire at the annual general meeting of shareholders to be held in 2028.
In
addition to Mr. Teleman’s appointment, the Board resolved to replace David Silberman with Ronnie Hershman as a member of the Compensation
Committee of the Board.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
NASUS PHARMA LTD. |
| |
|
|
| Date: September 5, 2025 |
By: |
/s/
Dan Teleman |
| |
Name: |
Dan Teleman |
| |
Title: |
Chief Executive Officer |
